| Advertisement |
|
|
|
|
July 5, 2005Eli Lilly Proposes New Strategyfiled under Bipolar Disorder Medications
The pharmaceutical company Eli Lilly has planned a new strategy for the development of future drugs. Many complain that drug companies spend less time searching for new drugs and more time making sure that they are overmarketed and overprescribed. Critics also complain that drug companies try to play-down side effects in order for their drugs to seem more attractive to the consumer. Recently, the chief executive of Eli Lilly--Sidney Taurel--delivered a speech to shareholders in which he stated "'the right dose of the right drug to the right patient at the right time.'' In other words, Lilly sees its future not in blockbuster medicines like Prozac that are meant for tens of millions of patients, but rather in drugs that are aimed at smaller groups and can be developed more quickly and cheaply, possibly with fewer side effects" (Berenson, 2005). Of course, this is just a statement that may or may not actually come into effect. Some people state that Eli Lilly has a bad track record of exaggerating the potential that its medications have. On the upside, since 2001 Eli Lilly has created five truly new drugs. They also spend nearly 20% of their sales on research, whereas the average drug company spends about 16%. The cost of developing new drugs has steadily increased over the years and is still increasing. This means it is only going to become more difficult for drug companies to discover and manufacture new medications. To change this trend, Eli Lilly plans to, "[focus] its research efforts on finding biomarkers -- genes or other cellular signals that will indicate which patients are most likely to respond to a given drug. Other drug makers are also searching for biomarkers, but Lilly executives are the most vocal in expressing their belief that this area of research will fundamentally change the way drugs are developed" (Berenson, 2005). We can only judge the truth of Eli Lilly's promises by what they deliver in the future. Hopefully they will hold true to their claims. The source of this article was The New York Times by Alex Berenson. Posted by at July 5, 2005 12:34 PM
More Information on Bipolar Disorder Medications
CommentsPost a comment |
ADVERTISEMENT
|
I really want draw your urgent attention to review another very basic and important aspect of care delivery where from you will eventually receive and collect data of when meds given to combat what symptom(is it really the symptom), and when at what doese given again to combat what aspect of symptom.
Now these above will depend on who is writing the daily progress notes and what is written in reference to dig out the reality of such symptoms, are they part of being ill or spontaneous response to some need or communication or some reaction to what has happened.
After eliminating lots of other factors that may look like symptoms we need to attend to, especially in cases of
1.mood changes
2.behabiour
3.agitation
4.outburst with need expression etc
In my experience I equate with the article came out from BMJ journal of 1st april written by G.Andrews about how we have failed to treat dementia and depended on meds structures fusing with other restrictions.
I like to draw your attention to the agenda we have when we prescribe this meds to clients.
I wish you organise world wide study days to make professionals aware of the danger in changing agenda and use meds to combat any thing and everything.
I had been involved in many creative discussions with Ely Lily first and all other pharmaceuticals too on this aspect.
Neurolink has made out good books for free distribution but withdrawals of meds has been termed as relapse which is not wholesomely true, we need to appreciate to cope with withdrawal effect for some only to get back life.
With kindest regards
I thank you for this article.
Tapan Pal
Nursing assistant
Mental Health
07956577095
07956577095@one2one.net
Posted by: Tapan Pal at April 15, 2006 2:00 AM